Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Restless Leg Syndrome (RLS) Clear all
Completed Phase 3 Interventional

Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

NCT00135993
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Jul 20, 2026, 6:42 PM EDT
Not listed Phase 4 Interventional

An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

NCT02560766
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 300 mg, HORIZANT 600 mg, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
12
States / cities
Redwood City, California • Gulf Breeze, Florida • Winter Park, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jul 20, 2026, 6:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glutamate, Hyperarousal and Restless Legs Syndrome

NCT01675323
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Terminated Phase 4 Interventional Results available

Oral Iron Frequency for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder

NCT04610827
View directory record Official record
Conditions
Sleep Disorder, Restless Legs Syndrome, Periodic Limb Movement Sleep Disorder, Iron-deficiency
Interventions
Ferrous sulfate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years to 10 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 1 Interventional

Ropinirole Tablets In Young Patients With Restless Legs Syndrome

NCT00140712
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Immediate Release
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Macon, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers

NCT01516372
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GEn 1200mg, Gen 6000 mg, GEn Placebo, Moxifloxacin Placebo, Moxifloxacin
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jul 20, 2026, 6:42 PM EDT
Not listed Phase 4 Interventional

Sublingual Apomorphine in Refractory Restless Legs Syndrome

NCT05529095
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Apomorphine Sublingual Film, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole

NCT00422994
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
ropinirole dosing for up to 28 days
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Tyrosine in Restless Legs Syndrome

NCT01494766
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
L-Tyrosine
Dietary Supplement
Lead sponsor
Seton Healthcare Family
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 3 Interventional

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

NCT00263068
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Timeline
2005 – 2007
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Not applicable Interventional Results available

Treatment of RLS/WED Symptoms Through Sensory Counter-stimulation

NCT03249779
View directory record Official record
Conditions
Restless Legs Syndrome, Willis-Ekbom Disease
Interventions
Scrambler
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)

NCT02499354
View directory record Official record
Conditions
Restless Legs Syndrome, Iron Deficiency Anemia
Interventions
Ferumoxytol intravenous, Ferrous sulfate
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

NCT01931878
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
incobotulinumtoxinA, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Jul 20, 2026, 6:42 PM EDT
Withdrawn Phase 1 Interventional

A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

NCT02633657
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 300 mg
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Redwood City, California • St Louis, Missouri • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jul 20, 2026, 6:42 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Spinal Cord Stimulators on Restless Leg Syndrome

NCT07179406
View directory record Official record
Conditions
Restless Leg Syndrome (RLS), Spinal Cord Stimulation (SCS)
Interventions
H-Reflex, Somatosensory evoked potential (SSEP), Vibratory Electrophysiological Response Potential (ERP), Transcranial Magnetic Stimulation (TMS), Spinal Cord Stimulator (SCS) manipulation
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Active, not recruiting No phase listed Observational

A Post-Market Study for Long-Term Effectiveness and Safety of the TOMAC System for RLS

NCT06076499
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
NTX100
Device
Lead sponsor
Noctrix Health, Inc.
Industry
Eligibility
21 Years and older
Enrollment
325 participants
Timeline
2023 – 2027
U.S. locations
7
States / cities
Downey, California • San Ramon, California • Newton, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 4 Interventional

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

NCT00375284
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
52
States / cities
Birmingham, Alabama • Dothan, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 3 Interventional

Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome

NCT00197080
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
60
States / cities
Alabaster, Alabama • Jasper, Alabama • Mesa, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

NCT01411124
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
gabapentin enacarbil, diphenhydramine, placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome

NCT00200941
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Topiramate
Drug
Lead sponsor
Neurocare
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2005 · Synced Jul 20, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome

NCT00834327
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
aplindore MR tablets or Placebo
Drug
Lead sponsor
Neurogen Corporation
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
24
States / cities
Phoenix, Arizona • Tuscon, Arizona • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2009 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia

NCT04706091
View directory record Official record
Conditions
Restless Legs Syndrome, Insomnia, Sleep Disorder
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 85 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Jul 20, 2026, 6:42 PM EDT
Recruiting Not applicable Interventional

Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome

NCT07144631
View directory record Official record
Conditions
Restless Leg Disorder, Restless Leg Syndrome (RLS), Pregnancy, Sleep Disorder (Disorder)
Interventions
Peroneal Nerve Stimulation (PNS) Device
Device
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 20, 2026, 6:42 PM EDT